Among these 9 mutations, eight were predicted to be "damaging" or "probably damaging," while one was categorized as "benign." This differs from findings in human liposarcoma, where TP53 mutations are described in 60% of pleomorphic liposarcomas and in approximately 20% of myxoid liposarcomas6. This evidence concerns the gene TP53 and pleomorphic liposarcoma.